Artificial Liver Support System Improves Short-Term Outcomes of Patients with HBV-Associated Acute-on-Chronic Liver Failure: A Propensity Score Analysis
Table 4
Effects of treatment on laboratory parameters at day 7.
Parameter
SMT (n = 272)
ALSS (n = 392)
value
Serum bilirubin (mg/dl)
Baseline
22.8 (7.3)
23.6 (7.0)
Day 7
23.9 (7.5)
22.2 (6.8)
Change from baseline
1.1 (7.2)
−1.4 (4.7)
0.008
Serum albumin (g/L)
Baseline
33.6 (5.4)
32.1 (5.3)
Day 7
33.8 (7.7)
34.1 (7.3)
Change from baseline
0.2 (4.5)
2.0 (17.3)
0.067
Baseline international normalized ratio
Baseline
2.3 (0.8)
2.4 (0.9)
Day 7
2.2 (0.8)
2.2 (0.8)
Change from baseline
−0.1 (0.50)
−0.2 (0.92)
0.064
Serum creatinine (μmol/L)
Baseline
72.6 (23.7)
68.5 (25.5)
Day 7
75.9 (28.5)
66.2 (24.8)
Change from baseline
3.3 (25.2)
−2.3 (17.9)
0.043
Alanine transaminase level (IU/L)
Baseline
371.8 (237.1)
360.4 (300.1)
Day 7
138.4 (137.1)
159.7 (196.7)
Change from baseline
−233.4 (293.7)
−200.7 (241.8)
0.071
MELD score
Baseline
25.2 (5.1)
25.0 (5.6)
Day 7
25.1 (4.7)
24.3 (5.8)
Change from baseline
−0.1 (3.4)
−0.7 (6.2)
0.036
SMT, standard medical therapy; ALSS, artificial liver support system; MLED, model for end-stage liver disease.
